Real‐World Experience of Dupilumab in Children and Adolescents With Atopic Dermatitis in Argentina

Current treatment guidelines suggest that patients with moderate‐to‐severe atopic dermatitis (AD) should be treated with systemic therapies, but evidence on its effectiveness in Latin America is limited. A nationwide, web‐based survey was distributed among dermatologists managing children and adolescents with moderate‐to‐severe AD treated with dupilumab in Argentina to characterize and describe children and adolescents with AD who received dupilumab in a real‐world setting. Data from 41 patients (median age: 11.23 years; female: 56.1%) revealed that 61% had developed AD by the age of 1 year or younger; atopic comorbidities were present in 70.7% (asthma 48.8%); methotrexate was the most frequently prescribed systemic therapy (58.5%); the median age at dupilumab initiation was 10 years (interquartile range [IQR]: 6.5–15) and median treatment duration was 1 year (IQR: 0–2). We conclude that treatment with dupilumab was highly effective in controlling moderate‐to‐severe AD refractory to conventional, guideline‐recommended systemic therapies, with adequate control in 87.8% of cases.